Tonix Pharmaceuticals (NASDAQ:TNXP) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Tonix Pharmaceuticals (NASDAQ:TNXP) from a sell rating to a hold rating in a report published on Saturday morning.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Tonix Pharmaceuticals in a report on Wednesday, January 21st. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Tonix Pharmaceuticals presently has an average rating of “Hold”.

Tonix Pharmaceuticals Stock Performance

Shares of TNXP opened at $14.34 on Friday. The firm has a market capitalization of $192.16 million, a price-to-earnings ratio of -1.00 and a beta of 1.75. Tonix Pharmaceuticals has a one year low of $11.60 and a one year high of $69.97. The stock’s fifty day moving average is $14.17 and its 200-day moving average is $16.47.

Tonix Pharmaceuticals (NASDAQ:TNXP) last issued its quarterly earnings results on Thursday, March 12th. The company reported ($3.98) EPS for the quarter, missing analysts’ consensus estimates of ($3.16) by ($0.82). The business had revenue of $5.39 million for the quarter, compared to analyst estimates of $2.97 million. Tonix Pharmaceuticals had a negative net margin of 946.22% and a negative return on equity of 60.15%. Analysts forecast that Tonix Pharmaceuticals will post -8.74 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Seth Lederman bought 15,000 shares of the firm’s stock in a transaction that occurred on Wednesday, March 18th. The stock was acquired at an average price of $14.89 per share, with a total value of $223,350.00. Following the completion of the purchase, the chief executive officer directly owned 15,001 shares of the company’s stock, valued at $223,364.89. This represents a 1,500,000.00% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. 2.00% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Tonix Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Man Group plc acquired a new position in shares of Tonix Pharmaceuticals in the 4th quarter valued at $288,000. Engineers Gate Manager LP boosted its position in shares of Tonix Pharmaceuticals by 63.7% in the 4th quarter. Engineers Gate Manager LP now owns 14,263 shares of the company’s stock valued at $223,000 after purchasing an additional 5,550 shares during the period. Balyasny Asset Management L.P. acquired a new position in shares of Tonix Pharmaceuticals in the 4th quarter valued at $2,895,000. AQR Capital Management LLC acquired a new position in shares of Tonix Pharmaceuticals in the 4th quarter valued at $313,000. Finally, Price T Rowe Associates Inc. MD acquired a new position in shares of Tonix Pharmaceuticals in the 4th quarter valued at $171,000. Institutional investors and hedge funds own 82.26% of the company’s stock.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals is a clinical-stage biotechnology company focused on developing therapeutics for central nervous system disorders, immunology and rare diseases. The company’s pipeline includes small-molecule and biologic product candidates designed to address conditions such as fibromyalgia, post-traumatic stress disorder (PTSD) and other chronic pain syndromes, as well as vaccines for potential viral and biothreat agents.

Among Tonix’s lead programs is TNX-102 SL, a sublingual formulation of cyclobenzaprine being evaluated for the treatment of fibromyalgia and PTSD.